ConductScience.org, home

Paper · 41454708

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130531990In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment.Nat Nanotechnol2019https://conductscience.org/library/papers/30531990PubMed
232627937Immunomodulation-Enhanced Nanozyme-Based Tumor Catalytic Therapy.Adv Mater2020https://conductscience.org/library/papers/32627937PubMed
331990409Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications.Adv Mater2020https://conductscience.org/library/papers/31990409PubMed
436441901Tumor Microenvironment-Activable Manganese-Boosted Catalytic Immunotherapy Combined with PD-1 Checkpoint Blockade.ACS Nano2022https://conductscience.org/library/papers/36441901PubMed
536996420Bioinspired Mild Photothermal Effect-Reinforced Multifunctional Fiber Scaffolds Promote Bone Regeneration.ACS Nano2023https://conductscience.org/library/papers/36996420PubMed
629784994Designing natural and synthetic immune tissues.Nat Mater2018https://conductscience.org/library/papers/29784994PubMed
736550304Systemic enhancement of antitumour immunity by peritumourally implanted immunomodulatory macroporous scaffolds.Nat Biomed Eng2023https://conductscience.org/library/papers/36550304PubMed
835595770Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis.Nat Commun2022https://conductscience.org/library/papers/35595770PubMed
9346017603D Printing Scaffold Vaccine for Antitumor Immunity.Adv Mater2021https://conductscience.org/library/papers/34601760PubMed
1030328620Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies.CA Cancer J Clin2018https://conductscience.org/library/papers/30328620PubMed
1129488312Simultaneous Fenton-like Ion Delivery and Glutathione Depletion by MnO2 -Based Nanoagent to Enhance Chemodynamic Therapy.Angew Chem Int Ed Engl2018https://conductscience.org/library/papers/29488312PubMed
1237265256Melanin-Based Immunoregulatory Nanohybrids Enhance Antitumor Immune Responses in Breast Cancer Mouse Model.ACS Nano2023https://conductscience.org/library/papers/37265256PubMed
1330713696An immunological electrospun scaffold for tumor cell killing and healthy tissue regeneration.Mater Horiz2018https://conductscience.org/library/papers/30713696PubMed
1429670088A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors.Nat Commun2018https://conductscience.org/library/papers/29670088PubMed
1538280861In-situ-sprayed therapeutic hydrogel for oxygen-actuated Janus regulation of postsurgical tumor recurrence/metastasis and wound healing.Nat Commun2024https://conductscience.org/library/papers/38280861PubMed
1629283170Perioperative events influence cancer recurrence risk after surgery.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/29283170PubMed
1731838435Synthetic 3D scaffolds for cancer immunotherapy.Curr Opin Biotechnol2020https://conductscience.org/library/papers/31838435PubMed
1838301259Turning Threat to Therapy: A Nanozyme-Patch in Surgical Bed for Convenient Tumor Vaccination by Sustained In Situ Catalysis.Adv Healthc Mater2024https://conductscience.org/library/papers/38301259PubMed
1936848115Biomineralized MnO2 Nanoplatforms Mediated Delivery of Immune Checkpoint Inhibitors with STING Pathway Activation to Potentiate Cancer Radio-Immunotherapy.ACS Nano2023https://conductscience.org/library/papers/36848115PubMed
2025739764Immunological mechanisms of the antitumor effects of supplemental oxygenation.Sci Transl Med2015https://conductscience.org/library/papers/25739764PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/41454708/references